{"nctId":"NCT01298219","briefTitle":"Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)","startDateStruct":{"date":"2010-12"},"conditions":["Opioid-induced Bowel Dysfunction"],"count":439,"armGroups":[{"label":"Lubiprostone","type":"EXPERIMENTAL","interventionNames":["Drug: Lubiprostone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lubiprostone","otherNames":["Amitiza"]},{"name":"Placebo","otherNames":["No other names"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nA patient can be considered for eligibility to participate if he/she:\n\n* Has been consistently treated for chronic, noncancer-related pain with any oral, transdermal, intravenous, or subcutaneous opioid for at least 30 days prior to screening\n* Is diagnosed with OBD\n* Is capable of utilizing an electronic diary to report daily spontaneous bowel movements (SBMs)\n* Is willing to continue opioid therapy and discontinue the use of laxatives, stool softeners, and other concomitant medications affecting gastrointestinal motility throughout the study\n\nExclusion Criteria:\n\nA patient cannot be considered for eligibility to participate if he/she:\n\n* Uses opioids for the treatment of cancer-related pain, abdominal pain, mechanical bowel obstructions, bowel disorders, and constipation not arising from opioid use, but instead attributable to dietary, neurologic, congenital, or endocrine disorders, scleroderma, and/or for the management of drug addiction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Classified as Treatment Responders Within 12 Weeks","description":"Spontaneous bowel movement (SBM) is defined as any BM that does not occur within 24 hours after use of rescue medication. To be classified as responders, participants are required to demonstrate at least moderate response (≥ 1 SBM improvement over baseline SBM frequency) for all treatment weeks for which observed data are available, and must additionally demonstrate a full response (≥ 3 SBMs per week) for at least 9 of the 12 treatment weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of SBMs Per Week at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"3.18"},{"groupId":"OG001","value":"2.5","spread":"3.03"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced First SBM Within 48 Hours After Dose Initiation","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of SBMs Per Week at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"3.13"},{"groupId":"OG001","value":"2.7","spread":"3.34"}]}]}]},{"type":"SECONDARY","title":"Number of SBMs Per Week Overall","description":"Overall is defined as the length of time from first dose to last follow-up within 2 weeks after last dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.96"},{"groupId":"OG001","value":"3.7","spread":"2.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":219},"commonTop":["Diarrhea","Nausea","Vomiting","Abdominal Pain","Urinary Tract Infection"]}}}